Crinetics Pharmaceuticals (CRNX)
(Real Time Quote from BATS)
$57.13 USD
+0.44 (0.78%)
Updated Nov 4, 2024 02:56 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRNX 57.13 +0.44(0.78%)
Will CRNX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CRNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRNX
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
CRNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline
Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Other News for CRNX
StemPoint Capital LP Increases Stake in Surrozen Inc
Crinetics Pharmaceuticals: Strong Buy Recommendation Driven by Best-in-Class Efficacy and Solid Financial Position
State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals
3 Best Stocks to Buy Now, 10/15/2024, According to Top Analysts
Crinetics Pharmaceuticals (CRNX) Gets a Buy from Piper Sandler